<110>   Blake, James

        Cole, Carol-Ann

        Coleman, Patrick F.

        Monji, Nobuo

        Montana, John P.

<120>   CYSTEINE THIOL-PROTECTED PEPTIDES FOR USE IN IMMUNOASSAYS

<130>   025580-001340US

<140>   09/733,239
<141>   2000-12-08

<150>   US 08/462,749
<151>   1995-06-05

<150>   US 08/140,696
<151>   1993-10-21

<150>   US 07/532,429
<151>   1990-06-04

<150>   US 07/360,513
<151>   1989-06-02

<160>   16

<170>   PatentIn version 3.1

<210>   1
<211>   26
<212>   PRT

<213> HIV-1

<400> 1

Arg Ile Leu Ala Val Glu Arg Tyr Leu Lys Asp Gln Gln Leu Leu Gly
1   5   10   15

Ile Trp Gly Cys Ser Gly Lys Leu Ile Cys
              20   25

<210> 2

<211> 26

<212> PRT

<213> HIV-2

<400> 2

Arg Val Thr Ala Ile Glu Lys Tyr Leu Gln Asp Gln Ala Arg Leu Asn
1   5   10   15

Ser Trp Gly Cys Ala Phe Arg Gln Val Cys
              20   25

<210> 3

<211> 17

<212> PRT

<213> HIV-2

<400> 3

Gln Asp Gln Ala Arg Leu Asn Ser Trp Gly Cys Ala Phe Arg Gln Val
1   5   10   15

Cys

<210> 4

<211> 23

<212> PRT

<213> HTLV-1

<400> 4

Gln Asn Arg Arg Gly Leu Asp Leu Leu Phe Trp Glu Gln Gly Gly Cys
1   5   10   15

Lys Ala Leu Gln Glu Gln Cys
            20

<210>   5

<211>   24

<212>   PRT

<213>   HTLV-2

<400>   5

Gln Asn Arg Arg Gly Leu Asp Leu Leu Phe Trp Glu Gln Gly Gly Leu
1   5   10   15

Cys Lys Ala Ile Gln Glu Gln Cys
            20

<210>   6

<211>   29

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Peptide 39 (SEQ 1) with Cys Gly Gly peptide arm

<400>   6

Cys Gly Gly Arg Ile Leu Ala Val Glu Arg Tyr Leu Lys Asp Gln Gln
1   5   10   15

Leu Leu Gly Ile Trp Gly Cys Ser Gly Lys Leu Ile Cys
            20   25

<210>   7

<211>   29

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Peptide 41-2-1 (SEQ 2) with Cys Gly Gly peptide arm

<400>   7

Cys Gly Gly Arg Val Thr Ala Ile Glu Lys Tyr Leu Gln Asp Gln Ala
1   5   10   15

Arg Leu Asn Ser Trp Gly Leu Ala Phe Arg Gln Val Cys
              20   25

<210>   8

<211>   20

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Peptide 41-2-3 (SEQ 3) with Cys Gly Gly peptide arm

<400>   8

Cys Gly Gly Gln Pro Gln Ala Arg Leu Asn Ser Trp Gly Cys Ala Phe
1   5   10   15

Arg Gln Val Cys
            20

<210>   9

<211>   27

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Peptide 121-1 (SEQ 4) with Cys Gly Gly peptide arm

<400>   9

Cys Gly Gly Gln Asn Arg Arg Gly Leu Asp Leu Leu Phe Trp Glu Gln
1   5   10   15

Gly Gly Leu Cys Lys Ala Leu Gln Glu Gln Cys
            20   25

<210>   10

<211>   27

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Peptide 221-1 (SEQ 5) with Cys Gly Gly peptide arm

<400> 10

Cys Gly Gly Gln Asn Arg Arg Gly Leu Asp Leu Leu Phe Trp Glu Gln
1   5   10   15

Gly Gly Leu Cys Lys Ala Ile Gln Glu Gln Cys
            20   25

<210> 11

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide 39 with Thr and C-terminal thioglycine residue

<400> 11

Arg Ile Leu Ala Val Glu Arg Tyr Leu Lys Asp Gln Gln Leu Leu Gly
1   5   10   15

Ile Trp Gly Cys Ser Gly Lys Leu Ile Cys Thr Gly
            20   25

<210> 12

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Pentadysine

<400> 12

Lys Lys Lys Lys Lys
1   5

<210> 13

<211> 20

<212> PRT

<213> HTLV-1

<400> 13

Gly Leu Asp Leu Leu Phe Trp Glu Gln Gly Gly Leu Cys Lys Ala Leu
1   5   10   15

Gln Glu Gln Cys
            20

<210>   14

<211>   23

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Peptide 121-2 (SEQ 13) with Cys Gly Gly peptide arm

<400>   14

Cys Gly Gly Gly Leu Asp Leu Leu Phe Trp Glu Gln Gly Gly Leu Cys
1   5   10   15

Lys Ala Leu Gln Glu Gln Cys
            20

<210>   15

<211>   16

<212>   PRT

<213>   HTLV-2

<400>   15

Asn Arg Arg Gly Leu Asp Leu Leu Phe Trp Glu Gln Gly Gly Leu Cys
1   5   10   15

<210>   16

<211>   19

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Peptide 121-3 (SEQ 15) with Cys Gly Gly peptide arm

<400>   16

Cys Gly Gly Asn Arg Arg Gly Leu Asp Leu Leu Phe Trp Glu Gln Gly
1   5   10   15

Gly Leu Cys